Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Summary

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector, outcomes assessor), placebo-controlled trial. TRACK is a global trial and will be conducted in renal units that provide comprehensive CKD care. Approximately 2000 participants will be recruited. The TRACK trial will assess a strategy of administering low dose rivaroxaban to reduce the risk of major adverse cardiac event (MACE) in people with Chronic Kidney Disease (CKD) stages 4 or 5 or dialysis-dependent kidney failure, and elevated cardiovascular (CV) risk (marked by a history of CAD or PAD, or non-haemorrhagic non-lacunar stroke OR diabetes mellitus OR age ≥65 years).

Timeline

Start

2021-01-18

Primary completion

2025-10-30

Completion

2025-10-30

Publications

• Badve SV, Perkovic V, Jha V, Ramachandran R, Mushahar L, Menne J, De Vriese AS, Rossignol P, Flahault A, Al Ammari M, Skhiri H, Walsh M, Collister D, Liew A, Billot L, Bompoint S, Devaux A, Jun M, Lin E, Ramos da Cruz A, Ha JT, Eikelboom JW, Shaman A, Jardine MJ, Jesudason S, Wong MG, Anderson CS, Garg AX, Heerspink HJL, Monaghan H, Patel A, Mark PB, Wheeler DC, Lv J, Zuo L, Pilmore H, Gallagher M; TRACK Trial Investigators. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA. 2026 Jun 4:e269379. doi: 10.1001/jama.2026.9379. Online ahead of print.

Drugs

Indications